Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

A beloved Manchester elementary school principal has lost her battle with cancer, city school officials confirmed. Jenny Lynch, who had been on medical leave from her role as principal at Webster ...